Time of interferon-β 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients
- 27 April 2007
- journal article
- clinical trial
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 13 (9), 1138-1145
- https://doi.org/10.1177/1352458507078685
Abstract
During initiation of interferon-beta (IFN-β) therapy, many multiple sclerosis (MS) patients experience systemic side effects which may depend on the time point of IFN-β injection. We investigated the time course of plasma hormone-, cytokine- and cytokine-receptor concentrations after the first injection of IFN-β either at 8.00 a.m. (group A) or at 6.00 p.m. (group B) and quantified clinical side effects within the first 9 h in 16 medication free patients with relapsing-remitting MS. This investigation was repeated after 6-month IFN-β therapy. Plasma ACTH and cortisol concentrations followed their physiological rhythms, with lower levels in the evening compared to the morning, but raised earlier and stronger in group B after IFN-β administration. IFN-β injection in the evening led to a prompter increase of plasma IL-6 concentrations and temperature during the first hours and correlated to more intense clinical side effects compared to group A. Plasma IL-10 concentrations increased more in group A compared to group B, but sTNF-RI and sTNF-RII concentrations raised 7 h after IFN-β injection only in group B. Acute effects on plasma hormone and cytokine concentrations adapted after 6-month IFN-β treatment, while diurnal variations were still present. Baseline sTNF-RII concentrations were elevated after 6-month IFN-β therapy only in group A. Our results show that time point of IFN-β injection has differential effects on acute changes of plasma hormone and cytokine concentrations and is related to systemic side effects. This may have implications on the tolerability and effectiveness of IFN-β therapy. Multiple Sclerosis 2007; 13: 1138—1145. http://msj.sagepub.comKeywords
This publication has 21 references indexed in Scilit:
- Circadian RhythmsAnnals of the New York Academy of Sciences, 2006
- Effects of Morning Versus Evening Intake of Atorvastatin on Major Cardiac Event and Restenosis Rates in Patients Undergoing First Elective Percutaneous Coronary InterventionThe American Journal of Cardiology, 2006
- The effects of interferon‐β on interleukin‐10 in multiple sclerosis patientsEuropean Journal of Neurology, 2005
- Changes in Toxicity and Effectiveness with Timing of Drug AdministrationDrug Safety, 2003
- Acute interferon β-1b administration alters hypothalamic-pituitary-adrenal axis activity, plasma cytokines and leukocyte distribution in healthy subjectsPsychoneuroendocrinology, 2002
- Towards a unified model of neuroendocrine–immune interactionImmunology & Cell Biology, 2001
- SHORT-TERM TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS PATIENTS WITH INTERFERON (IFN)-β1B TRANSIENTLY INCREASES THE BLOOD LEVELS OF INTERLEUKIN (IL)-6, IL-10 AND IFN-γ WITHOUT SIGNIFICANTLY MODIFYING THOSE OF IL-1β, IL-2, IL-4 AND TUMOUR NECROSIS FACTOR-αCytokine, 2000
- Interferon (IFN)-β treatment enhances CD95 and interleukin 10 expression but reduces interferon-γ producing T cells in MS patientsJournal of Neuroimmunology, 1999
- Amelioration of flulike symptoms at the onset of interferon β‐ 1b therapy in multiple sclerosis by low‐dose oral steroids is related to a decrease in interleukin‐6 inductionAnnals of Neurology, 1998
- DIURNAL RHYTHMS OF PRO-INFLAMMATORY CYTOKINES: REGULATION BY PLASMA CORTISOL AND THERAPEUTIC IMPLICATIONSCytokine, 1998